Digestery
Longevity supplements › NMN and Aging › Studies

Randomized trial · measured lab tests or safety

A 6-week NR trial in 22 healthy older adults lowered brain-disease blood markers

Vreones and colleagues · Aging cell · 2023

Original title: Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

NR raised NAD+ in nerve-cell-derived blood particles and lowered Aβ42, pJNK and pERK1/2 levels. These are brain-disease markers, not symptoms.

The study at a glance

Type of study
Randomized trial
Who or what was studied
22 people · Healthy older adults
What was tested
NR 500 mg twice a day for 6 weeks, vs placebo (crossover)
What it measured
Lab tests or markers
Daily amount
1000 mg a day
How long
6 weeks
Trial registration
NCT02921659
Who has a stake
No stake declared
No competing interests declared.
Journal
Aging cell, 2023
Source
PubMed record 36515353. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • –Small: 22 people. Small trials can miss real effects or find chance ones.
  • –Short: 6 weeks. Longer-term effects are unknown.
  • –Measured lab tests or markers, which stand in for aging and age-related decline. A better marker does not always mean better health.
  • ✓No competing interests declared.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    9

    3 benefit, 2 mixed, 4 no difference

  3. Trials in people: lab tests or safety

    7

    4 benefit, 1 mixed, 2 no difference

    ↑ This study is the ringed dot

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    6

    5 benefit, 1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does NMN slow aging?”

Not shown in people so far.

Confidence: very low. Based on 29 on-topic papers.

Read the full answer

Of the other 6 papers on the same step: 3 benefit, 1 mixed, 2 no difference. This one found benefit.

Other papers on the same step

See all 29 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.